Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-19T03:19:02.508Z Has data issue: false hasContentIssue false
  • English
  • Français

INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES

Published online by Cambridge University Press:  23 January 2012

Sonja V. Sorensen ,
Jo Wern Goh ,
Feng Pan ,
Connie Chen ,
Denise Yardley ,
Miguel Martín ,
Kevin Knopf ,
Ágnes Benedict ,
Carla Giorgetti  and
Shrividya Iyer
Sonja V. Sorensen
Affiliation:
United BioSource [email protected]
Jo Wern Goh
Affiliation:
United BioSource Corporation
Feng Pan
Affiliation:
United BioSource Corporation
Connie Chen
Affiliation:
Pfizer Oncology
Denise Yardley
Affiliation:
The Sarah Cannon Research Institute and Tennessee Oncology, PLLC
Miguel Martín
Affiliation:
Hospital General Universitario Gregorio Marañón, Universidad Complutense
Kevin Knopf
Affiliation:
United BioSource Corporation
Ágnes Benedict
Affiliation:
United BioSource Corporation
Carla Giorgetti
Affiliation:
Pfizer Oncology
Shrividya Iyer
Affiliation:
Pfizer Oncology
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: This study aims to estimate the annual U.S. societal costs associated with treatment of metastatic breast cancer (MBC) patients using an incidence-based cost-of-illness (COI) framework.

Methods: An incidence-based COI model was constructed in which MBC patients were simulated from diagnosis through active treatment, palliative care, and death over 5 years. Key model parameters included: annual incidence of breast cancer in the metastatic stage, utilization of cancer therapies and other medical care resources, treatment-related adverse events, unit costs, work days missed by patient and caregiver, and wage rates. Overall survival was based on SEER data and costs were assigned to living patients monthly, according to their disease management phase. The outcomes measures were total discounted societal costs, cost/year, and cost/patient-year.

Results: The annual incidence of MBC in the United States in 2007 was estimated to be 49,674 patients (de novo and progressed from earlier stages). The total discounted cost to society attributable to MBC was $12.2 billion for the incident cohort, or $98,571 per patient-year. The 5-year direct medical cost of this incident cohort was $9.3 billion, or $75,415 per patient-year. Treatment-related costs (active treatment, toxicity management, and medical follow-up) contributed 44 percent of MBC expenditure, followed by palliative/best supportive care costs (31 percent). Lost productivity accounted for approximately 21 percent of the total cost ($2.6 billion over 5 years or $21,153 per patient-year).

Conclusions: The societal burden of MBC in the United States is substantial. Earlier detection and effective treatment could lead to a significant decrease in costs while improving overall disease prognosis.

Keywords

Metastatic breast cancerCost-of-illnessLost productivityEconomic model
Type
ASSESSMENTS
Information
International Journal of Technology Assessment in Health Care , Volume 28 , Issue 1 , January 2012 , pp. 12 - 21
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Allen, JM. Economic/societal burden of metastatic breast cancer: A US perspective. Am J Manag Care. 2010;16:697–704.Google ScholarPubMed
2.Barron, JJ, Quimbo, R, Nikam, PT, Amonkar, MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109:367–377.CrossRefGoogle Scholar
3.Bennett, CL, Calhoun, EA. Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients. Oncologist. 2007;12:478–483.CrossRefGoogle ScholarPubMed
4.Berkowitz, N, Gupta, S, Silberman, G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3:23–30.CrossRefGoogle ScholarPubMed
5.Brewster, AM, Hortobagyi, GN, Broglio, KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100:1179–1183.Google Scholar
6.Bureau of Labor Statistics. News release: The employment situation - April 2011. Washington, DC: U.S. Department of Labor; 2011.Google Scholar
7.Bureau of Labor Statistics. Table 22: Persons at work in nonagricultural industries by age, sex, race, Hispanic or Latino ethnicity, marital status, and usual full- or part-time status. U.S. Department of Labor; 2010.Google Scholar
8.Bureau of Labor Statistics & U.S. Census Bureau. Current Population Survey, Design and Methodology. Technical Paper TP63RV. Washington, DC: U.S. Department of Labor and U.S. Department of Commerce, Economics and Statistics Administration; 2010.Google Scholar
9.Campbell, JD, Ramsey, SD.The costs of treating breast cancer in the US: A synthesis of published evidence. Pharmacoeconomics. 2009;27:199–209.CrossRefGoogle Scholar
10.Davis, KL, Iyer, S, Candrilli S. Predictors of the direct costs of breast cancer in the United States elderly population. Value Health. 2010;13:A260.CrossRefGoogle Scholar
11.Elting, LS, Shih, YC. The economic burden of supportive care of cancer patients. Support Care Cancer. 2004;12:219–226.Google Scholar
12.Hartmann, LC, Zahasky, KM, Grendahl, DC. Management of cancer pain. Safe, adequate analgesia to improve quality of life. Postgrad Med. 2000;107:267–272, 75-76.CrossRefGoogle ScholarPubMed
13.Hayman, JA, Langa, KM, Kabeto, MU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. 2001;19:3219–3225.Google Scholar
14.Kruse, GB, Amonkar, MM, Smith, G, et al. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008;14:844–857.Google Scholar
15.Kurian, AW, Thompson, RN, Gaw, AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25:634–641.Google Scholar
16.Lamerato, L, Havstad, S, Gandhi, S, et al. Economic burden associated with breast cancer recurrence: Findings from a retrospective analysis of health system data. Cancer. 2006;106:1875–1882.Google Scholar
17.Mauri, D, Polyzos, NP, Salanti, G, et al. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008;100:1780–1791.CrossRefGoogle ScholarPubMed
18.Montazeri, A. Health-related quality of life in breast cancer patients: A bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32.Google Scholar
19.National Cancer Institute. Cancer trends progress report – 2009/2010 uapdate. Bethesda, MD: NIH, DHHS; April 2010.Google Scholar
20.National Cancer Institute. Surveillance Epidemiology and End Results (SEER) - Breast cancer. 2007–2010. Bethesda, MD: National Cancer Institute.Google Scholar
21.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2011. Fort Washington, PA: National Comprehensive Cancer Network.Google Scholar
22.Printz, C. Healthcare reform affects cancer on many fronts. More coverage for treatment and prevention planned. Cancer. 2010;116:3525–3526.CrossRefGoogle ScholarPubMed
23.Rao, S, Kubisiak, J, Gilden, D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83:25–32.CrossRefGoogle ScholarPubMed
24.Schwartz, J. Current combination chemotherapy regimens for metastatic breast cancer. Am J Health Syst Pharm. 2009;66 (Suppl 6):S3–S8.CrossRefGoogle ScholarPubMed
25.Sloss, EM, Wickstrom, SL, McCaffrey, DF, et al. Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditions. Cerebrovasc Dis. 2004;18:8–15.Google Scholar
26.Stokes, ME, Thompson, D, Montoya, EL, et al. Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-medicare data. Value Health. 2008;11:213–220.CrossRefGoogle ScholarPubMed
27.Wang, SJ, Fuller, CD, Choi, M, Thomas, CR. A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer. Gastrointest Cancer Res. 2008;2:57–63.Google Scholar
28.Yabroff, KR, Lawrence, WF, Clauser, S, et al. Burden of illness in cancer survivors: Findings from a population-based national sample. J Natl Cancer Inst. 2004;96:1322–1330.Google Scholar
Supplementary material: File

Sorensen et al. supplementaey material

SUpplementary data

Download Sorensen et al. supplementaey material(File)
File 48.6 KB